IL162062A0 - Methods for identifying and validating potential drug targets - Google Patents

Methods for identifying and validating potential drug targets

Info

Publication number
IL162062A0
IL162062A0 IL16206202A IL16206202A IL162062A0 IL 162062 A0 IL162062 A0 IL 162062A0 IL 16206202 A IL16206202 A IL 16206202A IL 16206202 A IL16206202 A IL 16206202A IL 162062 A0 IL162062 A0 IL 162062A0
Authority
IL
Israel
Prior art keywords
identifying
methods
drug targets
potential drug
validating potential
Prior art date
Application number
IL16206202A
Other languages
English (en)
Original Assignee
Proteologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteologics Inc filed Critical Proteologics Inc
Publication of IL162062A0 publication Critical patent/IL162062A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
IL16206202A 2001-11-19 2002-11-19 Methods for identifying and validating potential drug targets IL162062A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33170101P 2001-11-19 2001-11-19
PCT/US2002/037146 WO2003043580A2 (en) 2001-11-19 2002-11-19 Methods for identifying and validating potential drug targets

Publications (1)

Publication Number Publication Date
IL162062A0 true IL162062A0 (en) 2005-11-20

Family

ID=23295003

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16206202A IL162062A0 (en) 2001-11-19 2002-11-19 Methods for identifying and validating potential drug targets

Country Status (7)

Country Link
US (1) US20030194725A1 (https=)
EP (1) EP1456647A4 (https=)
JP (1) JP2005525790A (https=)
AU (1) AU2002352797A1 (https=)
CA (1) CA2468107A1 (https=)
IL (1) IL162062A0 (https=)
WO (1) WO2003043580A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049607A1 (en) * 2001-03-12 2003-03-13 Tsvika Greener Compositions and methods for the modulation of viral maturation
US20040043386A1 (en) * 2002-08-30 2004-03-04 Todd Pray Methods and compositions for functional ubiquitin assays
CN1926551B (zh) * 2003-10-27 2010-06-16 罗斯塔生化科技有限责任公司 用于基因沉默的siRNA的设计方法
EP2044247A4 (en) * 2006-07-11 2010-07-21 Avalon Pharmaceuticals CHEMIO-SELECTIVE IDENTIFICATION OF THERAPEUTIC PRODUCTS
WO2018168777A1 (ja) * 2017-03-13 2018-09-20 学校法人関西学院 嚢胞性線維症予防又は治療剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
US5723750A (en) * 1995-01-12 1998-03-03 Vanderbilt University Transgenic plants expressing disassembly deficient viral coat proteins
US5726025A (en) * 1995-04-20 1998-03-10 President And Fellows Of Harvard College Assay and reagents for detecting inhibitors of ubiquitin-dependent degradation of cell cycle regulatory proteins
US6001619A (en) * 1995-10-04 1999-12-14 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto
US6278039B1 (en) * 1997-05-28 2001-08-21 Axys Pharmaceuticals, Inc. C. elegans deletion mutants
US6573094B1 (en) * 1997-10-16 2003-06-03 Baylor College Of Medicine F-box genes and proteins
CA2308582A1 (en) * 1997-11-06 1999-05-20 Fred Hutchinson Cancer Research Center Method for identifying drug targets
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
WO2000008181A2 (en) * 1998-08-07 2000-02-17 Onyx Pharmaceuticals, Inc. Chp polypeptide, a ligand of pak65
AU767507B2 (en) * 1998-08-28 2003-11-13 New York University Novel ubiquitin ligases as therapeutic targets
AU6158799A (en) * 1998-10-13 2000-05-01 Onyx Pharmaceuticals, Inc. Novel cell signaling polypeptides and nucleic acids
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
CA2362520A1 (en) * 1999-02-26 2000-08-31 Joan W. Conaway Novel component of von hippel-lindau tumor suppressor complex and scf ubiquitin ligase
EP1988165A1 (en) * 1999-03-31 2008-11-05 The University of North Carolina at Chapel Hill Isolated DNA encoding cullin regulator ROC1, isolated proteins encoded by the same, and methods utilizing the same
AU6611900A (en) * 1999-07-30 2001-03-13 Agy Therapeutics, Inc. Techniques for facilitating identification of candidate genes
PT1309726E (pt) * 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US6740495B1 (en) * 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US6610489B2 (en) * 2000-04-28 2003-08-26 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
EP1364049A2 (en) * 2000-07-31 2003-11-26 Gene Logic, Inc. Molecular toxicology modeling
US6258601B1 (en) * 2000-09-07 2001-07-10 Isis Pharmaceuticals, Inc. Antisense modulation of ubiquitin protein ligase expression
WO2003022987A2 (en) * 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
EP1442062A4 (en) * 2001-10-18 2005-11-09 Genentech Inc METHOD FOR TREATING CARCINOMA

Also Published As

Publication number Publication date
WO2003043580A3 (en) 2004-04-15
JP2005525790A (ja) 2005-09-02
AU2002352797A1 (en) 2003-06-10
EP1456647A4 (en) 2006-10-18
WO2003043580A2 (en) 2003-05-30
US20030194725A1 (en) 2003-10-16
CA2468107A1 (en) 2003-05-30
EP1456647A2 (en) 2004-09-15

Similar Documents

Publication Publication Date Title
GB2407684C (en) Transaction method and system
EP1368909A4 (en) SYSTEM AND METHODS OF LOCALIZATION
EP1621239A4 (en) GAME SYSTEM AND GAME SERVER
IL221199A0 (en) Pharmaceutical identification
IL158089A0 (en) Optimized system and method for finding best fares
EP1570084A4 (en) METHOD FOR IDENTIFYING FUNCTION-RELATED GENES AND DRUG OBJECTIVES
GB0129437D0 (en) Server and units
ZA200405297B (en) Game providing system and game server
EP1386144A4 (en) IDENTIFICATION AND VERIFICATION METHODS
AU2002320156A1 (en) Risk evaluation system and methods
AU2003287010A8 (en) Game payout value modification system and methods
GB0229834D0 (en) Target and method
AU2002342053A1 (en) Pancreatic cancer diagnosis and therapies
IL159153A0 (en) Methods for testing drugs for treating or preventing diseases such as hyperlipidemia
EP1344060A4 (en) METHOD FOR DETERMINING THE FUNCTION OF TARGETS AND IDENTIFYING SERIAL HEADS OF DRUGS
AU2002363522A8 (en) System and method for improved computer drug design
IL162062A0 (en) Methods for identifying and validating potential drug targets
EP1636766A4 (en) ACCOUNT IDENTIFICATION AND VALIDATION
GB0127125D0 (en) Electronic gaming system
AU2003221570A8 (en) Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies
GB0314452D0 (en) Payment system and method
AU2001214291A1 (en) Electronic transaction system and methods thereof
AU2002365217A1 (en) Multi-disciplinary approach to validating or identifying targets using an in vivo system
GB0201715D0 (en) Strategies for the discovery and validation of drug targets using genetically altered mice
HK1080908A (en) Methods for identifying functionally related genes and drug targets